Cargando…
New options for the medical treatment of Cushing's syndrome
A number of drugs have been advocated for the medical management of Cushing's syndrome but few have gained widespread acceptance. The most reliably effective agents are metyrapone and ketoconazole as monotherapy, or in combination. Cabergoline may be of value in a minority of patients but pasir...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683198/ https://www.ncbi.nlm.nih.gov/pubmed/23776896 http://dx.doi.org/10.4103/2230-8210.109685 |
_version_ | 1782273469479649280 |
---|---|
author | Trainer, Peter J. |
author_facet | Trainer, Peter J. |
author_sort | Trainer, Peter J. |
collection | PubMed |
description | A number of drugs have been advocated for the medical management of Cushing's syndrome but few have gained widespread acceptance. The most reliably effective agents are metyrapone and ketoconazole as monotherapy, or in combination. Cabergoline may be of value in a minority of patients but pasireotide is a more reliable and effective agent that lowers cortisol secretion in the great majority of patients, although only normalises UFC in a minority. The potential for combination of an agent that blocks adrenal steroidogenesis with inhibition of ACTH secretion by pasireotide needs to be explored. |
format | Online Article Text |
id | pubmed-3683198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-36831982013-06-17 New options for the medical treatment of Cushing's syndrome Trainer, Peter J. Indian J Endocrinol Metab ESICON 2012 Kolkata Mini-Review A number of drugs have been advocated for the medical management of Cushing's syndrome but few have gained widespread acceptance. The most reliably effective agents are metyrapone and ketoconazole as monotherapy, or in combination. Cabergoline may be of value in a minority of patients but pasireotide is a more reliable and effective agent that lowers cortisol secretion in the great majority of patients, although only normalises UFC in a minority. The potential for combination of an agent that blocks adrenal steroidogenesis with inhibition of ACTH secretion by pasireotide needs to be explored. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3683198/ /pubmed/23776896 http://dx.doi.org/10.4103/2230-8210.109685 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | ESICON 2012 Kolkata Mini-Review Trainer, Peter J. New options for the medical treatment of Cushing's syndrome |
title | New options for the medical treatment of Cushing's syndrome |
title_full | New options for the medical treatment of Cushing's syndrome |
title_fullStr | New options for the medical treatment of Cushing's syndrome |
title_full_unstemmed | New options for the medical treatment of Cushing's syndrome |
title_short | New options for the medical treatment of Cushing's syndrome |
title_sort | new options for the medical treatment of cushing's syndrome |
topic | ESICON 2012 Kolkata Mini-Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683198/ https://www.ncbi.nlm.nih.gov/pubmed/23776896 http://dx.doi.org/10.4103/2230-8210.109685 |
work_keys_str_mv | AT trainerpeterj newoptionsforthemedicaltreatmentofcushingssyndrome |